Last reviewed · How we verify
CHOP, CMAB304
CMAB304 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
CMAB304 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity. Used for Cancer (specific indication not publicly detailed).
At a glance
| Generic name | CHOP, CMAB304 |
|---|---|
| Also known as | cyclophosphamide, doxorubicin, vincristine, prednisone |
| Sponsor | Shanghai CP Guojian Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of CMAB304 is not widely disclosed in public literature, it is developed as an immunotherapeutic monoclonal antibody by Shanghai CP Guojian Pharmaceutical. As a Phase 3 candidate, it is likely designed to modulate immune responses against cancer cells, potentially through checkpoint inhibition or direct tumor antigen targeting.
Approved indications
- Cancer (specific indication not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |